Home > Insider Trading > Filing (0001209191-22-062044)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1539029	Clearside Biomedical Inc.	CLSD	Pharmaceutical Preparations (2834)	452437375

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1592380	Clay Thorp	C/O Clearside Biomedical, Inc. 900 North Point Parkway, Suite 200 Alpharetta GA 30005		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-02-10	32,873	$4.43	4,951,547	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on March 16, 2020.
Consists of (i) 447 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 21,095 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 1,916 shares sold by Hatteras Venture Affiliates III, LP ("HVA III") and (iv) 9,415 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC").
This transaction was executed in multiple trades at prices ranging from $4.40 to $4.50, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
The original Form 4 inadvertently misstated the total number of shares. This reflect the accurate number of shares beneficially owned.